Edwards Lifesciences Corp Receives Consensus Rating of “Buy” from Brokerages (NYSE:EW)
Shares of Edwards Lifesciences Corp (NYSE:EW) have received a consensus rating of “Buy” from the eighteen analysts that are presently covering the company, AR Network reports. Five investment analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $91.50.
Shares of Edwards Lifesciences Corp (NYSE:EW) opened at 98.41 on Monday. Edwards Lifesciences Corp has a 52-week low of $60.62 and a 52-week high of $99.11. The stock has a 50-day moving average of $90. and a 200-day moving average of $80.71. The company has a market cap of $10.435 billion and a P/E ratio of 14.20.
Edwards Lifesciences Corp (NYSE:EW) last released its earnings data on Tuesday, July 29th. The company reported $0.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.11. The company had revenue of $547.00 million for the quarter, compared to the consensus estimate of $545.10 million. During the same quarter in the previous year, the company posted $0.82 earnings per share. The company’s revenue for the quarter was up 11.2% on a year-over-year basis. Analysts expect that Edwards Lifesciences Corp will post $3.29 EPS for the current fiscal year.
In other Edwards Lifesciences Corp news, VP Larry L. Wood unloaded 63,752 shares of the stock on the open market in a transaction dated Monday, August 18th. The shares were sold at an average price of $97.85, for a total value of $6,238,133.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
EW has been the subject of a number of recent research reports. Analysts at JMP Securities raised their price target on shares of Edwards Lifesciences Corp from $97.00 to $120.00 in a research note on Thursday. They now have an “outperform” rating on the stock. Separately, analysts at Stifel Nicolaus raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday, July 31st. Finally, analysts at JPMorgan Chase & Co. raised their price target on shares of Edwards Lifesciences Corp from $78.00 to $90.00 in a research note on Thursday, July 31st.
Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.